anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention comprises quinoxaline derivatives of the general formula <FORM:0914303/IV (b)/1> wherein R1 is a hydrogen or halogen atom or an alkyl or haloalkyl radical containing up to 6 carbon atoms, an alkoxy radical with up to 6 carbon atoms or a nitro radical, R2 is an alkyl radical with up to 4 carbon atoms, an aralkyl or aryl radical, R3 is an alkoxy radical with up to 6 carbon atoms or a <FORM:0914303/IV (b)/2> radical and X and Y are oxygen or sulphur. These quinoxalines may be prepared by reacting the appropriate 2-mercapto-quinoxaline with phosgene, thiophosgene, a chloro-formic acid ester or a thiocarbonic ester halide preferably in inert solvents e.g. alkaline solutions with an acid binding agent being present. Specified binding agents are alkali and alkaline earth metal hydroxides and carbonates and tertiary amines.  In Example 1, 2-thiocarboxyethyl-3-methoxy-quinoxaline is prepared by adding ethyl chloroformate to an alkaline solution of 3-methoxy-2-mercapto-quinoxaline.  In Example 2, a compound of formula <FORM:0914303/IV (b)/3> is prepared by adding thiophosgene to 3-methoxy-2-mercapto quinoxaline in alkaline solution.  In Example 3 a compound of formula <FORM:0914303/IV (b)/4> is prepared as above using phosgene in place of thiophosgene. These compounds are used as fungicides (see Group VI). Specification 885,789 is referred to.ALSO:Pesticidal compositions contain as active ingredient a quinoxaline of formula <FORM:0914303/VI/1> wherein R1 is a hydrogen or halogen atom, an alkyl, haloalkyl or alkoxy radical with up to 6 carbon atoms or a nitro radical, R2 is an alkyl radical with up to 4 carbon atoms, an aralkyl or aryl radical, R3 is an alkoxy radical with up to 6 carbon atoms or a <FORM:0914303/VI/2> radical and X and Y are oxygen or sulphur.  These quinoxalines may be used in a concentration of 0.00001 to 1%, diluted or extended with solid or liquid carriers.  Specified solid carriers are talc, chalk, bentonite and clay and specified liquid carriers are water, alcohols, especially methanol and ethanol, ketones, especially acetone and methyl ethyl ketone and liquid hydrocarbons.  The quinoxalines may be used in combination with each other or with known insecticides and/or fertilizers.  A quinoxaline of formula <FORM:0914303/VI/3> was dissolved in acetone, benzene hydroxy diphenyl polyglycol ether as emulsifier was added and the mixture diluted with water to give a solution containing 0.02% of the quinoxaline.  Bush beans infested with eggs of the two-spotted spider were sprayed with an aqueous emulsion as prepared above.  Specification 885,789 is referred to.
PURPOSE: To obtain a solubilizing agend good in safety and usability by using a water-soluble and amphiphilic polyelectrolyte obtained by copolymerizing two kinds of specified (meth)acrylamide-based monomers or further neutralizing the resultant copolymer with an alkaline agent. CONSTITUTION: This solubilizing agent uses a water-soluble and amphiphilic polyelectrolyte obtained by copolymerizing a (meth)acrylamidoalkylsulfonic acid and/or its salt with an N-substituted (meth)acrylamide or further neutralizing the resultant copolymer with an alkaline agent. The polyelectrolyte preferably contains at least >=15wt.% (meth)acrylamidoalkylsulfonic acid unit based on the total weight. Further, the polyelectrolyte preferably contains at least >=40wt.% N-substituted (meth)acrylamide unit based on the total weight. The solubilized composition is preferably obtained by blending 0.01-20wt.% solubilizing agent therein. The solubilized cosmetic can be produced by blending the solubilized composition therein.
Killip classification has been used to stratify the risk of patients with acute myocardial infarction (AMI). There were many reports that Killip class 3 or 4 is closely associated with poor clinical outcomes. In other words, Killip class 1 or 2 is associated with favorable clinical outcomes in patients with AMI, especially when patients received primary percutaneous coronary intervention (PCI). However, some patients with Killip class 1/2 suffer from serious in-hospital complications. This study aimed to identify factors associated with serious in-hospital complications of ST-segment elevation myocardial infarction (STEMI) in patients with Killip class 1/2. The primary endpoint was serious in-hospital complications defined as the composite of in-hospital death and mechanical complications. We included 809 patients with STEMI, and divided them into the non-complication group (n = 791) and the complication group (n = 18). In-hospital death was observed in 14 patients (1.7%), and mechanical complications were observed in 4 patients (0.5%). Final TIMI flow ≤ 2 was more frequently observed in the complication group (33.3%) than in the non-complication group (5.4%) (p < 0.001). Multivariate logistic regression analysis revealed that serious in-hospital complication was associated with final TIMI flow grade ≤ 2 (Odds ratio 6.040, 95% confidence interval 2.042-17.870, p = 0.001). In conclusion, serious in-hospital complication of STEMI was associated with insufficient final TIMI flow grade in patients with Killip class 1/2. If final TIMI flow grade is suboptimal after primary PCI, we may recognize the potential risk of serious complications even when patients presented as Killip class 1/2.
Topiramate is a medication that is approved for the treatment of seizures. In accordance with international guidelines, studies are conducted after a drug is marketed to continue to evaluate and expand the knowledge regarding its safety. This is a multi-center, open-label observational safety study to collect information regarding the dosage, tolerability and effectiveness of topiramate in adults and children with epilepsy (or seizures). Patients who have not received previous treatment for epilepsy or for whom previous treatment was ineffective or intolerable will receive 6 months of treatment with topiramate. Topiramate will be given at low doses initially and gradually increased as needed for each patient to control seizure activity. Safety evaluations (incidence of adverse events and laboratory tests) and assessment of patient health status will be performed throughout the study. Effectiveness will be evaluated by recording the frequency of seizures occurring during the study. Patient and physician satisfaction with topiramate treatment will also be recorded. At the end of the study, the treating physician may continue treatment with topiramate in responding patients as appropriate. The study hypothesis is that topiramate will be effective in achieving and maintaining control of seizure activity and is well-tolerated. Observational study - No investigational drug administered.
Atorvastatin calcium, the substance known by the chemical name [(R-(R*,R*)]-2-(4-fluorophenyl)-b, ddihy-dorxy-5-(1-methylethyl)-3-pheny]-4-(pneny]aiTrino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt is known as HMG-CoA reductase inhibitor and is used as an antihypercholesterolemic agent. Atorvastatin is usually prepared as its calcium salt since it enable atorvastatin to be conveniently formulated in the pharmaceutical formulations, for example, in tablets, capsules, powders and the like for oral administration. Atorvastatin calcium can exist in an amorphous form or in one of the crystalline forms (Form I, Form II, Form ??II and Form IV). Atorvastaling calcium is the substance which is very slightly water-soluble, and it has been found that the crystalline forms are less readily soluble than the amorphous form which may cause problems in the bioavailability of atorvastatin in the body. The present invention relates to a novel process tor converting the intermediate in the synthesis of atorvastatin having the following formula (I) or atorvastatin lactose into the non-crystalline atorvastatin calcium: wherein A denotes a common protection group or separate protection groups for the dihydroxy group and ?? denotes a carboxylic acid protection group.
The pathogenesis of Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) remains unclear, though increasing evidence suggests inflammatory processes play key roles. In this study, single-cell RNA sequencing (scRNA-seq) of peripheral blood mononuclear cells (PBMCs) was used to decipher the immunometabolic profile in 4 ME/CFS patients and 4 heathy controls. We analyzed changes in the composition of major PBMC subpopulations and observed an increased frequency of total T cells and a significant reduction in NKs, monocytes, cDCs and pDCs. Further investigation revealed even more complex changes in the proportions of cell subpopulations within each subpopulation. Gene expression patterns revealed upregulated transcription factors related to immune regulation, as well as genes associated with viral infections and neurodegenerative diseases.CD4+ and CD8+ T cells in ME/CFS patients show different differentiation states and altered trajectories, indicating a possible suppression of differentiation. Memory B cells in ME/CFS patients are found early in the pseudotime, indicating a unique subtype specific to ME/CFS, with increased differentiation to plasma cells suggesting B cell overactivity. NK cells in ME/CFS patients exhibit reduced cytotoxicity and impaired responses, with reduced expression of perforin and CD107a upon stimulation. Pseudotime analysis showed abnormal development of adaptive immune cells and an enhanced cell-cell communication network converging on monocytes in particular. Our analysis also identified the estrogen-related receptor alpha (ESRRA)-APP-CD74 signaling pathway as a potential biomarker for ME/CFS in peripheral blood. In addition, data from the GSE214284 database confirmed higher ESRRA expression in the monocyte cell types of male ME/CFS patients. These results suggest a link between immune and neurological symptoms. The results support a disease model of immune dysfunction ranging from autoimmunity to immunodeficiency and point to amyloidotic neurodegenerative signaling pathways in the pathogenesis of ME/CFS. While the study provides important insights, limitations include the modest sample size and the evaluation of peripheral blood only. These findings highlight potential targets for diagnostic biomarkers and therapeutic interventions. Further research is needed to validate these biomarkers and explore their clinical applications in managing ME/CFS.
The study duration with each patient will be 48 hours (two nights); at the first night the sleep study will be with PAT device, with snoring recording and without the "Forrest" epic device. In the second night the sleep study will be with PAT device, with snoring recording and with the "Forrest" epic device. The order of the sleep studies (with and without the epic device) will be randomly determined by computerized ahead prepared list. The research duration for patients that did not have a sleep study over the last year, will take place for 3 nights; the sleep study will be performed in order to make sure the patient does not suffer from obstructive respiratory disorder during sleep. The sleep studies will take place in a sleep laboratory (Millennium Sleep Labs LTD, Beer Sheva) or as an ambulatory study, at home.
PURPOSE:To provide a dental adhesive containing methylene chloride and a polycarbonate resin at a specific ratio, and capable of bonding a dental polysulfone resin extremely firmly to a dental acrylic resin. CONSTITUTION:(A) A dental polysulfone resin for denture base, having the structure of formula I, formula II, etc. and having high strength and excellent impact resistance but poor adhesivity to acrylic resin, is bonded with (B) a dental acrylic resin for artificial tooth, etc., by using a dental adhesive containing (C) 100pts.wt. of methylene chloride and (D) 0.3-20pts.wt., preferably 0.5-15pts.wt. of a polycarbonate resin. an extremely high adhesive strength between A and B can be attained by the adhesive. The component C has low boiling point and rapid dryability, is applicable to the resin A without causing cracks, is a good solvent of the component D to enable the preparation of homogeneous solution, and has excellent affinity to the resin B and high safety.
Patients with pathohistologically diagnosed T1 conventional oral squamous cell carcinoma. The investigators will collect saliva from the mouth floor (saliva sampling), measure SCCA1, SCCA2 and TROP2 using ELISA tests and measure Ap4A levels using HPLC.
Before starting the study, the "Structured Patient Information Form", "Edmonton Symptom Diagnosis Scale", and "Oxford Happiness Scale Short Form" were applied to the patients. Treatment was given to this group of patients only after informing them about the study, and the patients were followed for only three months. "Edmonton Symptom Diagnosis Scale" and "Oxford Happiness Scale Short FormS" were applied to the patients three times: before, at the 6th week, and the end of the 12th week of the research.
A medical imaging communication system generates an automated report for a medical image corresponding to a patient. The system receives one or more medical images for a patient. The system applies a model to identify an abnormality in the received one or more medical images. The model is configured to determine a likelihood score for the presence of the abnormality in the one or more medical images. If the likelihood score is above a threshold value, the system generates an automated report indicating the type of abnormality identified in the received one or more medical images. The automated report is then provided to a viewing user (e.g., a medical professional viewing the one or more medical images).
Embodiments of the present invention provide for assessing the state of an 8 2Rb elution system. In certain embodiments, a system begins an assessment that comprises an elution, and a metric may be measured. This metric may be a concentration of 82Rb, 82Sr, or 85Sr in a fluid that is eluted from the generator, the volume of the fluid that is eluted from the generator, or the pressure of the fluid flowing through at least one portion of the system. If the assessment is completed, an output may be generated on a user interface that recommends a course of action, or no course of action, based on a result of the assessment. Should the assessment not complete successfully because it is interrupted, a 8 2 Sr/8 2Rb generator of the system may be halted so as to prevent a user from performing an end-run around these quality control mechanisms of the 8 2Rb elution system. Further, in response to determining that a total volume of the fluid exceeds a limit threshold, elution is prevented until the generator is replaced with a new generator.
The study consisted of two single-day study periods separated by a 7-day washout. At the first study day, a single oral dose of vitamin C gummy (1007.2mg) was orally administered following a 12 hour fasting period. After a 7 day washout period, a single oral dose of vitamin C caplet (1027.9mg) was orally administered following a 12 hour fasting period.
OBJECTIVE: Psychiatric evaluation of candidate patients before bariatric surgery (BS) has an important place in the success of the treatment. In this study, it was aimed to examine the relationship between childhood trauma (CT) and body image, self-esteem and eating attitudes of individuals who applied for BS.
METHOD: A total of 87 BS candidate patients with morbid obesity, 57 women and 30 men, were included in the study. Sociodemographic Information Form, Childhood Trauma Questionnaire (CTQ), Body Perception Scale (BPS), Rosenberg Self-Esteem Scale (RSES), and Eating Attitude Test (EAT-40) were used as data collection tools in the study.
RESULTS: CT was detected in 47.1% of the cases. RSES (t=3.296; p<0.01) and BPS (t=3.267; p<0.01) scores were found to be significantly higher in those with a history of CT. A positive and significant relationship was found between EAT-40 and CTQ -sexual abuse (SA) sub-dimension (r=0.570; p<0.01). A significant relationship was found between all subdimensions of CTQ and RSES. A significant relationship was found between CTQ physical neglect (PN), emotional neglect (EN), and emotional abuse (EA) sub-dimensions and BPS. In addition, CTQ total score was found to significantly and negatively predict self-esteem (β=- 4.432; p<0.001) and body image (β=-3.700; p<0.001).
CONCLUSION: In our study, it was found that those with CT were dissatisfied with their bodies and had lower self-esteem. Questioning CT in the psychological evaluation of pre-BS cases may contribute to the understanding of the etiology of obesity and may play an important role in planning the follow-up after BS.
Dose escalation part: Eligible patients will start to receive oral LCL161 once a week and will receive weekly paclitaxel, at 80 mg/m2 intravenous infusion over 1 hour, in combination with LCL161 from cycle 2. Dose expansion part: Eligible patients will receive oral LCL161 at the maximum tolerated dose and/or recommended dose in combination with weekly paclitaxel, at 80 mg/m2 intravenous infusion over 1 hour from cycle 1.
The present invention relates to a process for obtaining of disinfectant composition from grapefruit seeds. The process according to the present invention comprises the step of separating the seed and pulp of certain types of tree-ripened grapefruit from the remainder of the fruit and drying the seed and pulp for 24-48 hours at a temperature in the range of 150 DEG -200 DEG C. The seed and pulp are then tested for pesticides and only non-contaminated seed and pulp are selected for processing. The dried, non-contaminated seed and pulp is mixed at a ratio of 80:20 seed/pulp by weight. The mixture is then ground in a hammermill to small particles, whereupon the ground mixture is placed inside some type of mesh bag or perforated container which is then placed in a reaction vessel. Previously, a glycerin solution in an amount by weight approximately equal to the weight of the ground mixture has been placed in the vessel and heated to a temperature of at least approximately 150 DEG C. The vessel is sealed and the glycerin solution is then circulated through the extraction chamber and past an external ultraviolet system and magnetic system which helps to stabilize the ingredients and to remove ferrous metallic particles thereof. Glycerin circulation is continued at the same temperature for approximately 3-4 hours, whereupon the temperature is reduced to approximately 60 DEG C. while the pressure within the chamber is increased to a range of 2.500-3.000 lbs/sq. inch. There results a syrup and a residue in the reaction chamber. The syrup is then passed through a force filter system having a 300 -350 mesh nylon filter to obtain a heavy viscous lemon yellow liquid having a pH in the range of 2.5-3.0.
PURPOSE: Ectopic pregnancies include cesarean scar (CSP), cornual and cervical pregnancies. Various treatment modalities have been- described, but no standardized procedure has been defined so far. The aim of our analysis was to evaluate the diagnostics and treatment at the Department of Obstetrics and Gynecology, LMU University Hospital, Munich.
METHODS: In this retrospective, single-center analysis, 24 patients treated between 2015 and 2020 were analyzed. After verification of the diagnosis by imaging and HCG-analysis, the treatment was individually determined: therapy with methotrexate (MTX) locally with or without simultaneous systemic treatment, surgical treatment via curettage, excision with uterine reconstruction even hemi hysterectomy.
RESULTS: Ten patients presented with CSP, six with cervical and eight with cornual pregnancies. Median age was 34.6 years. CSP was treated with local MTX in six cases; five required additional treatment with systemic MTX or curettage. Primary curettage or surgery was performed in four cases. In cervical pregnancies the primary therapy with local MTX injection and systemic treatment was performed in 50%. One patient was treated with MTX and insertion of a Bakri balloon. Trachelectomy was required in one case. 50% of cornual pregnancies were treated with MTX locally and intramuscularly and 50% received surgery.
CONCLUSION: Treatment strategies were based on the patient's individual risk parameters. The results of this study show, that simultaneous treatment with local and systemic MTX had good outcomes and could avoid surgeries.
Emerging evidence demonstrates that pyroptosis has been implicated in the pathogenesis of asthma. Gasdermin D (GSDMD) is the pyroptosis executioner. The mechanism of GSDMD in asthma remains unclear. The aim of this study was to elucidate the potential role of GSDMD in asthmatic airway inflammation and remodeling. Immunofluorescence staining was conducted on airway epithelial tissues obtained from both asthma patients and healthy controls (HCs) to evaluate the expression level of N-GSDMD. ELISA was used to measure concentrations of cytokines (IL-1β, IL-18, IL-17A, and IL-10) in serum samples collected from asthma patients and healthy individuals. We demonstrated that N-GSDMD, IL-18, and IL-1β were significantly increased in samples with mild asthma compared with those from the controls. Then, wild type and Gsdmd-knockout (Gsdmd-/-) mice were used to establish asthma model. We performed histopathological staining, ELISA, and flow cytometry to explore the function of GSDMD in allergic airway inflammation and tissue remodeling in vivo. We observed that the expression of N-GSDMD, IL-18, and IL-1β was enhanced in OVA-induced asthma mouse model. Gsdmd knockout resulted in attenuated IL-18, and IL-1β production in both bronchoalveolar lavage fluid (BALF) and lung tissue in asthmatic mice. In addition, Gsdmd-/- mice exhibit a significant reduction in airway inflammation and remodeling, which might be associated with reduced Th17 inflammatory response and M2 polarization of macrophages. Further, we found that GSDMD knockout may improve asthmatic airway inflammation and remodeling through regulating macrophage adhesion, migration, and macrophage M2 polarization by targeting Notch signaling pathway. These findings demonstrate that GSDMD deficiency profoundly alleviates allergic inflammation and tissue remodeling. Therefore, GSDMD may serve as a potential therapeutic target against asthma.